RxDoctor Payments Data

Heather Jones, MD

Psychiatry · Roswell, GANPI 1689710790

Payments from drug & device makers

$3,194in general payments, 2019–2025

Across 160 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$957
  • Teva Pharmaceuticals USA, Inc.$576
  • Otsuka America Pharmaceutical, Inc.$540
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$282
  • Neurocrine Biosciences, Inc.$250
  • Avanir Pharmaceuticals, Inc.$131
  • plus $458 from 11 others

What the payments were for

  • Food & beverage$3,13498%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,194 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$48,615
Medicare patients
74
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$100,686
Abilify MaintenaAripiprazole32$92,678
Invega SustennaPaliperidone Palmitate23$67,255
VraylarCariprazine Hcl41$63,394
RexultiBrexpiprazole31$58,136
TrintellixVortioxetine Hydrobromide31$23,753
Aripiprazole216$6,692
SeroquelQuetiapine Fumarate12$6,657
Quetiapine Fumarate275$4,747
Divalproex Sodium ErDivalproex Sodium50$3,446
Mirtazapine175$3,427
Olanzapine158$3,247
Duloxetine Hcl179$3,197
Ziprasidone Hcl34$3,136
Vilazodone Hcl31$2,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$540$150,81463 claims
Neurocrine Biosciences, Inc.Ingrezza$250$100,68613 claims
Johnson & JohnsonInvega Sustenna$86$67,25523 claims
AbbVieVraylar$957$63,39441 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$23,75331 claims
Lilly USA, LLCOlanzapine$16$3,247158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →